Oxford Biomedica PLC (OXB) — Investment Research Note

Executive summary

Oxford Biomedica is a pure-play cell and gene therapy CDMO specialising in viral vector (lentivirus, AAV, adeno) development and GMP manufacturing for pharma/biotech clients across sites in the UK, France and the US. Across the period, OXB transformed from a mixed platform/product business into a focused CDMO; revenues grew sharply in 2021 on COVID-19 vaccine manufacturing for AstraZeneca, retrenched sharply in 2023 as that work ended, then rebuilt via organic CDMO growth and the ABL Europe and Durham, NC acquisitions, with 2025 revenues ~£167m and FY2026 guidance £180–200m 2026-09-22 interim, 2026-02-24 trading update. The single most important point for valuation today is that the stock sits between a weakened near-term delivery record (August 2026 guidance cut, Durham delay, France impairment) and a credible, high-operating-leverage path to c.£500m revenue / c.30% EBITDA margins by 2030 — the price broadly discounts the first but asks the investor to pay for very little of the second.

Fair value estimate

• Methodology: blend of (i) EV/forward-revenue multiple on 2026E and (ii) DCF to 2030 ambition discounted at 12%.
• Key assumptions: FY2026 revenue £190m, FY2027 revenue £240m (midpoint of 25–30% growth), 2030 revenue £500m, 2030 EBITDA margin 22–28% (vs. c.30% ambition), 10–12x EV/EBITDA exit multiple, ~£50m net debt rising towards £80–100m before FCF inflection, 12% WACC.
• Scenario DCF: 2030E EBITDA £110–140m → EV £1.3–1.6bn → PV today ~£830m–£1.05bn equity.
• Multiple cross-check: 3.5–4.5x 2026E sales = EV £665–855m → equity ~£615–805m.
• Fair value range: 480p – 700p per share, implying a market cap range of £580m – £850m.
• Mid-point: ~590p / £715m vs latest disclosed market cap of £630.7m.
• Absolute upside at midpoint: ~+13% (range: -8% to +34%).

Sector context

Confirmed as Health Care (Life Sciences Tools & Services sub-industry). OXB is a specialised viral-vector CDMO — a narrower profile than diversified CDMOs. Quality is above typical biotech peers given 30 years of viral vector heritage, two commercial products supplied (Kymriah lentivector, BMS CAR-T), and multi-site global capability. Growth is above sector but earnings quality and leverage are below — it is still loss-making with modest net debt and material lease liabilities (£105m). Closest listed peers: Lonza (CHE), Samsung Biologics (KOR), Catalent (US, since taken private); on a UK/pure-play CGT CDMO basis OXB is essentially unique on the LSE.

Investment thesis (3 bullets)

• Capacity-constrained specialist platform with real operating leverage — H1 2026 revenue £80m but adjusted EBITDA still -£2.5m, with management explicitly guiding mid-single-digit EBITDA margin for 2026, double-digit for 2027 and c.30% long term as utilisation builds across UK/France/Durham 2026-09-22 interim. The incremental contribution margin on each additional batch is high given a largely fixed site cost base.
• Pipeline maturation and visibility are strengthening — 59 client programmes (vs 44 a year ago), 9 late-stage/commercial, revenue backlog £193m, FY2026 revenue £168m already covered by contracted orders, non-risk-adjusted pipeline up ~30% YoY to c.$713m 2026-09-22 interim. Durham, NC is now GMP-online, opening US commercial-scale capacity.
• Validated by strategic shareholders and anchor customers — Institut Mérieux owns ~11% and backs the France strategy; Serum Life Sciences committed £50m for Oxbox expansion; and BMS signed a commercial supply agreement for lentivector supporting its CAR-T portfolio 2026-09-22 interim, 2025-09-23 interim.

Key risks (3 bullets)

• Execution and delivery credibility weakened — the August 2026 trading update cut FY2026 revenue guidance from £220–240m to £180–200m citing client ordering delays and a six-month delay at Durham; France impairment of £7.6m in H1 2026 confirms lower near-term expectations 2026-08-07 trading update, 2026-09-22 interim. The medium-term bridge now has one fewer year of track record behind it.
• Balance sheet is thin for a loss-making business — cash fell from £96.9m (Dec-25) to £75.3m (Jun-26) to £66.8m (Aug-26); H1 2026 net cash outflow was £34.3m; a further $15m was drawn from the Oaktree $125m facility; covenants require minimum liquidity 2026-09-22 interim. Another miss would re-open financing risk.
• Client concentration and biotech-funding cyclicality — two clients contributed £56.2m of H1 2026 revenue (70% of the total); the business is directly exposed to the biotech funding environment and to clinical/BLA outcomes at a handful of partners 2026-09-22 interim.

Operating leverage

This is the strongest element of the thesis. H1 2026 cost of sales was £50.7m on £79.8m revenue (gross margin 37%, down from 43% H1 2025 on mix) but underlying operating costs ex-cost-of-sales were only ~£33m (operating, innovation, commercial and admin, ex depreciation and impairment); of this, manpower (£41.3m total expenses) and site costs (£10.1m) are predominantly fixed. Depreciation and amortisation ran at £11.4m in H1 (c.£23m annualised), reflecting a mostly built-out asset base. Management's own bridge is explicit: FY2026 EBITDA margin mid-single-digit excl. one-offs → at least double-digit in FY2027 → approaching c.30% by 2030/31 — i.e. a ~£300m incremental revenue bridge to 2030 drops ~£125m to EBITDA, an incremental margin of >40%. A 10–20% revenue beat above 2027 guidance would plausibly add 50–100% to 2027 EBITDA given the fixed cost base, consistent with the user's "long-tail of outcomes" screen 2026-09-22 interim, 2026-02-24 trading update, 2025-09-23 interim.

Value-trap signals

• Repeated near-term guidance resets (Aug 2026 cut; Durham six-month delay) create "it's always just one more year" risk.
• Continued operating losses despite five years of revenue growth; cash conversion weak in H1 2026 (-£34m).
• Rising lease and loan servicing costs (lease interest £4.7m, loan interest £3.1m H1 2026) compress FCF regardless of EBITDA progress.
• France CGU impairment £7.6m signals the original growth plan for the acquired French sites was too optimistic.
• Not a terminal-decline story but execution-track-record erosion is real.

Earnings vs. expectations

Across the period the pattern is: a one-off 2021 beat on COVID-19 vaccine volumes, a 2022–23 miss as that revenue rolled off and the restructure played out, a strong 2024–25 recovery delivering at the upper end of guidance (FY2025 revenue £166–169m vs £160–170m guidance, EBITDA breakeven delivered as promised) 2026-02-24 trading update; then a meaningful miss in 2026 when FY2026 revenue was cut from £220–240m to £180–200m on client ordering delays and Durham slippage 2026-08-07 trading update. Net: more in-line than beat, with one visible miss and one recent profit warning — this is a "meets with occasional misses" record rather than a serial beater.

Conviction

Conviction: 3 (moderate).

• Anchors: tight disclosure of backlog, pipeline and contracted-revenue coverage; appropriate CDMO revenue-multiple and DCF methodology; management's own 2030 bridge is quantified and internally consistent.
• Limits: fair value depends heavily on 2027–2030 margin trajectory which is 4+ years out and has just suffered a credibility hit; wide range of plausible outcomes between a 2027 reacceleration case and a prolonged margin-expansion stall. A different cost of capital or exit multiple shifts fair value materially.